CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

Molecular Cancer Therapeutics
Linhua JinMarina Konopleva

Abstract

Chronic myelogenous leukemia (CML) is driven by constitutively activated Bcr-Abl tyrosine kinase, which causes the defective adhesion of CML cells to bone marrow stroma. The overexpression of p210Bcr-Abl was reported to down-regulate CXCR4 expression, and this is associated with the cell migration defects in CML. We proposed that tyrosine kinase inhibitors, imatinib or INNO-406, may restore CXCR4 expression and cause the migration of CML cells to bone marrow microenvironment niches, which in turn results in acquisition of stroma-mediated chemoresistance of CML progenitor cells. In KBM5 and K562 cells, imatinib, INNO-406, or IFN-alpha increased CXCR4 expression and migration. This increase in CXCR4 levels on CML progenitor cells was likewise found in samples from CML patients treated with imatinib or IFN-alpha. Imatinib induced G0-G1 cell cycle block in CML cells, which was further enhanced in a mesenchymal stem cell (MSC) coculture system. MSC coculture protected KBM-5 cells from imatinib-induced cell death. These antiapoptotic effects were abrogated by the CXCR4 antagonist AMD3465 or by inhibitor of integrin-linked kinase QLT0267. Altogether, these findings suggest that the up-regulation of CXCR4 by imatinib promotes migration...Continue Reading

References

Apr 29, 1999·The New England Journal of Medicine·C L Sawyers
Nov 24, 1999·Experimental Hematology·L C Platanias, E N Fish
Apr 6, 2001·Blood·K OkudaJ D Griffin
Jul 10, 2003·Blood Cells, Molecules & Diseases·Kiyotaka KawauchiShin ichiro Ohkawa
Oct 10, 2003·The New England Journal of Medicine·John M Goldman, Junia V Melo
Apr 20, 2004·Blood·Teru HideshimaKenneth C Anderson
Nov 6, 2004·Blood·Lucy J ElrickTessa L Holyoake
Jan 29, 2005·Proceedings of the National Academy of Sciences of the United States of America·Kiranmai GumireddyE Premkumar Reddy
Jun 28, 2005·Proceedings of the National Academy of Sciences of the United States of America·Natalia L Komarova, Dominik Wodarz
Jul 1, 2005·Nature·Franziska MichorMartin A Nowak
Jul 14, 2005·Biochemical Pharmacology·Sigrid HatseDominique Schols
Aug 12, 2005·Molecular Cancer Therapeutics·Maher N YounesJeffrey N Myers
May 19, 2006·Cancer Research·Suparna MishraJohn Groffen

❮ Previous
Next ❯

Citations

Apr 29, 2010·Current Hematologic Malignancy Reports·Mhairi Copland
Apr 29, 2010·Current Hematologic Malignancy Reports·G Vignir HelgasonTessa L Holyoake
Apr 3, 2012·Current Hematologic Malignancy Reports·Leslie A Crews, Catriona H M Jamieson
Dec 25, 2012·Current Hematologic Malignancy Reports·Ross Kinstrie, Mhairi Copland
Sep 24, 2010·Leukemia·I SlomaC J Eaves
Sep 17, 2010·Leukemia·D M RossJ V Melo
Jan 19, 2013·Leukemia·S MustjokiUNKNOWN Nordic CML Study Group (NCMLSG)
Dec 14, 2011·The Cancer Journal·David W WoessnerMichael W Deininger
Feb 4, 2010·The Oncologist·Robert L Redner
Dec 8, 2011·Haematologica·Angelo M CarellaDanilo Perrotti
Sep 6, 2012·International Journal of Molecular Sciences·Magali CastellsBettina Couderc
Oct 8, 2013·Oncogene·S J VidalJ Domingo-Domenech
Feb 1, 2013·Advances in Hematology·Felix Nwajei, Marina Konopleva
May 22, 2008·Stem Cell Reviews·John Stagg
Feb 9, 2011·Leukemia & Lymphoma·Joana M Diamond, Junia V Melo
Feb 9, 2011·Leukemia & Lymphoma·Nicholas J Donato, Luke F Peterson
Jan 7, 2014·Expert Opinion on Biological Therapy·Alessandro MorottiGiuseppe Saglio
Aug 22, 2012·Cancer Letters·Leslie A Crews, Catriona H M Jamieson
Apr 7, 2012·Archives of Medical Research·Jessica PurizacaRosana Pelayo
Jan 9, 2016·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·R ShirzadN Saki
May 19, 2011·Toxicology and Applied Pharmacology·Mirja NurmioTiina Laitala-Leinonen
Jul 28, 2009·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Marina KonoplevaMichael Andreeff
Dec 10, 2008·Drug Discovery Today·Lois A Lampson
Dec 17, 2008·Seminars in Cancer Biology·Hyunsuk ShimNobutaka Fujii
Jul 21, 2015·Immunology Letters·Andrés García-GarcíaSimón Méndez-Ferrer
Oct 16, 2015·Blood Cells, Molecules & Diseases·Jun How LowAmmu Kutty Radhakrishnan
Mar 23, 2013·British Journal of Pharmacology·A SinclairT L Holyoake
Aug 29, 2009·Medicinal Research Reviews·S SchenoneM Botta
Jan 11, 2014·British Journal of Haematology·Yoko Tabe, Marina Konopleva
Nov 7, 2015·Mediators of Inflammation·Gregor HoermannPeter Valent
Sep 29, 2009·Leukemia Research·Asumi YokotaTaira Maekawa
Dec 17, 2014·Immunological Reviews·Tessa L Holyoake, G Vignir Helgason

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.